Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Purpose of this study is to determine appropriate dosing of ABI-009 and evaluate the safety
and anti-tumor activity of ABI-009 in treatment of non-muscle invasive bladder cancer